Search Results for “EU” – Page 378 – media

Does Loss of REM Sleep Affect Overall Health?

In a recently published paper, researchers outline the importance of REM sleep and the causes and consequences of loss of REM sleep.
- Source: medicalnewsbulletin
- 473
- November 29, 2017
REM Sleep Researches Sleep deprivation
New Genes Associated With Cognitive Ability Identified

Investigators at The Feinstein Institute for Medical Research discovered dozens of new genetic variations associated with a person’s general cognitive ability. The findings, which were published online today in Cell Reports, have the potential to help researchers develop more targeted treatment for cognitive and memory disorders.
- Source: neurosciencenews
- 516
- November 29, 2017
Alzheimer's disease cognitive disorders Researches schizophrenia
Doctolib raises another $42 million for its medical care scheduling service

French startup Doctolib is raising money for the second time in the past twelve months. The company is building a sort of Salesforce for the healthcare industry with a big emphasis on bookings. Doctolib just raised $42 million (€35 million) from Eurazeo and existing investor Bpifrance.
- Source: Technologythrill
- 457
- November 29, 2017
Doctolib Market Views Series
Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis

Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral, monomethyl fumarate (MMF) small drug molecule in Phase 3 development for the treatment of relapsing forms of multiple sclerosis (MS).
- Source: businesswire
- 507
- November 29, 2017
ALKS 8700 Biogen Market Views
Kyowa Hakko Kirin Announces FDA Acceptance for Filing and Priority

Review Designation of Mogamulizumab’s Biologics License Application
- Source: drugdu
- 482
- November 29, 2017
Biologics License Application FDA New Approvals
Zika Virus Kills Brain Cancer Stem Cells MEDICINE & HEALTH

While Zika virus causes devastating damage to the brains of developing fetuses, it one day may be an effective treatment for glioblastoma, a deadly form of brain cancer. New research from Washington University School of Medicine in St. Louis and the University of California San Diego School of Medicine shows that the virus kills brain cancer stem cells, the kind of cells most resistant to standard treatments.
- Source: scienmag
- 572
- November 28, 2017
brain cancer glioblastoma Researches
Medical Products for Human Use

New technologies, therapies and medicines are emerging; this includes regenerative medicine, more personalised treatments, as well as the development of nanomedicines. The Commission is committed to monitoring scientific progress and to constantly review Community legislation in the light of new developments so as to make safe, novel treatments available to patients as early as possible.
- Source: ec.europa.eu
- 634
- November 28, 2017
nanomedicine polices regenerative medicine
Prometic Reports Positive Interim Clinical Data From Ongoing Intravenous Immunoglobulin Pivotal Phase III Trial

Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) announced positive interim six-month clinical data from its ongoing pivotal IVIG Phase 3 clinical trial in patients suffering from primary immunodeficiencies (PID) following review of the data by the Data Safety Monitoring Board (DSMB), which confirmed no significant safety issues and that efficacy appeared to be comparable to existing commercial IVIG products.
- Source: Prometic
- 499
- November 28, 2017
Clinical Trials IVIG PID
Changes in diet may improve life expectancy in Parkinson’s patients

New research from the University of Aberdeen shows that weight loss in people with Parkinson's disease leads to decreased life expectancy, increased risk of dementia and more dependency on care.
- Source: medicalxpress
- 555
- November 27, 2017
Dementia Parkinson's Researches
China Food and Drug Administration Approves Gilead’s Sovaldi® (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection

Gilead Sciences, Inc. (NASDAQ: GILD) announced that the China Food and Drug Administration (CFDA) has approved Sovaldi® (sofosbuvir 400mg), a once-daily oral nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Sovaldi was approved for the treatment of adults and adolescents (aged 12 to 18 years) infected with HCV genotype 1, 2, 3, 4, 5 or 6 as a component of a combination antiviral treatment regimen. Sovaldi is the first Gilead HCV medicine approved in China.
- Source: Gilead
- 776
- November 27, 2017
CFDA Gilead Sciences HCV New Approvals Sovaldi®

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.